Ed Raskin

Edward Raskin advises life sciences companies on corporate strategy, regulatory planning, and investor engagement across the growth continuum, from private stage to pre-IPO readiness. Ed supports clients with compliance and governance strategy, risk management, regulatory planning, board engagement, and fundraising strategy. He frequently collaborates with early-stage companies and investor syndicates on transaction readiness, clinical trial development, and growth.

Prior to joining Stout, Ed served in executive and interim advisory roles for multiple therapeutic and device companies, providing leadership in crossover financing strategy, public offering readiness, and strategic partnership development. He has worked closely with global pharmaceutical partners, including Eli Lilly, Novo Nordisk, and Zealand Pharma, and he has helped shape licensing, IP, and R&D strategies to support novel drug-device combination therapies.

Previously, Ed was a co-founder, board member, and corporate strategy officer at Beta Bionics (BBNX), where he led multiple rounds of financing and spearheaded the company’s successful Breakthrough Device Designation from the FDA. He also led strategic partnerships and commercialization planning for the first fully autonomous insulin delivery system to receive regulatory approval and go to market.